Congress must act to prohibit Chinese companies from receiving Inflation Reduction Act tax credits.
The House China Select Committee released its 52 page strategy report for 2024. Here’s what’s inside, and what might be missing.
In meeting about the new 2024 strategy report by the House Select Committee on the CCP, disagreements on decoupling, tariffs, and trade with China.
Katherine Tai sticks up for domestic economy in international trade relations during Aspen Security Forum.
In Senate hearing: imported generic drugs facing consistent drug shortages need a government incentive program to help labs make life-saving commodity drugs domestically.
The October trade deficit rose, but the biggest takeaway from the latest data is how much the China goods gap is in decline this year.
A recent study suggests that Americans prefer locally produced medications if they are unclear where the product was made or if the lab has received bad reviews from an FDA inspection.
The December Currency Misalignment Monitor found dollar overvaluation edging up once again, to 17.4% against the basket of 33 other currencies included in our model.
It should be a no-brainer to make sure that America’s investors don’t fund any of China’s military ambitions. And yet our very own Congressman, Patrick McHenry of North Carolina, is inexplicably blocking bipartisan congressional efforts to limit U.S. investments in China.
Key Points The standard widely-used trade model, GTAP, has been wrong in its forecasts of every major U.S. trade agreement. CPA economists have modified the model to allow it to show more realistically the effects of trade policy on employment and the entire economy. Our modified GTAP model, GTAP-FP, finds that import restriction or policies…
